US 2008/0187549 A1 · Polyantigenic-based (multiple antigens) modi or set of methods for developing infertility vaccines

Abstract

Said invention is a unique modi or set of immunological techniques/methods, by which to develop various types of infertility vaccines, primarily designed to reduce fertility or to produce infertility in animals and/or in humans. Said reduced fertility or infertility may be permanent or exists with variable duration. The immunological infertility responses, resulting from said uniquely developed vaccines (as affected/created by the proposed methodologies), may be superior to currently existing infertility vaccines {referenced, herein}, since they (the vaccines resulting from the proposed methods, herein) would contain a far greater diversity/variety of antigens; and are therefore, considered as polyantigenic vaccines, herein. A larger diversity/variety of antigens may better elicit a greater diversity/variety of endogenous antibodies. A greater variety of antibody types and antibody variable sites may enhance the infertility response. Correspondingly, the proposed methods may result in infertility vaccines which affect greater numbers and types of memory cells. While currently existing infertility vaccines use individual or limited numbers of identified antigens to sperm, or to sex-related hormones, etc. Said proposed modi or set of methods are unique, not only because they are polyantigenic, but because of some of the specified antigenic sources employed, besides sperm, i.e., ova, gamete germinal cells, gamete precursor cells, male ejaculate, liquor folliculi, certain differentiated stem cells, etc. The proposed modi does not use isolated/identified sperm antigens, as is currently used in infertility vaccines. Heretofore, the proposed modi has not been proposed. Because humans and many domesticated animals (cats, dogs, cattle, sheep, birds, etc.) are such out-bred species, in that they may possess a broad variety of gamete-based antigens, individual responsiveness to an immunologic vaccine which uses a single or highly limited number (one or two) of isolated/identified antigens, is apt to be ineffective. Limited antigen types may fail to adequately address the vaccine recipient's own gamete-based antigens. The use of the proposed polyantigenic modi may enhance vaccine efficacy by providing a greater diversity of antigens, and thereby affecting a broader spectrum of response antibodies, etc.

This application claims the use of whole live sperm as a possible component in the creation of various infertility vaccines. Said sperm may be human (autologous and/or allogenic), and/or animal (trans-specie;

other than human), or any combination of these sperm sources. Said whole live sperm may be used as the only type of antigen source in the infertility vaccine or may be used in various amounts and concentrations, and in various combinations and concentrations with the various other antigen sources, mentioned herein.
This application claims the use of whole dead sperm as a possible component in the creation of various infertility vaccines. Said dead whole sperm may be human (autologous and/or allogenic), and/or animal (trans-specie, other than human), or any combination of these sperm sources. Said whole dead sperm may be used as the only type of antigen source in infertility vaccines or may be used in various amounts and concentrations, and in various combinations and concentrations with the other antigen sources, mentioned herein.
This application claims the use of sperm fractions and/or biochemical components of said sperm, as components in various infertility vaccines. Said sperm fractions may be human (autologous and/or allogenic), and/or animal (trans-specie, other than human), or any combination of these sperm fraction sources. Said sperm fractions may be used as the only type of antigen source in the infertility vaccine or may be used in various amounts and concentrations, and in various combinations and concentrations with the various other antigen sources, mentioned herein.
Methods of fractioning or separating or digesting or concentrating said sperm fractions are not a part of this application. Examples of said fractions may be:
the head of the sperm, the tail of the sperm, the partially digested plasma membrane of the sperm, the separated protein fraction(s) of the sperm, the complex carbohydrates fraction of the sperm, etc. This application does not claim the use of a particular isolated sperm-based protein or set of isolated sperm-based proteins.
This application claims the use of male ejaculate (with and/or without sperm) or fractions or portions of said ejaculate, as possible components in various infertility vaccines. Said male ejaculate and/or male ejaculate fractions may be human (autologous and/or allogenic), and/or animal (trans-specie, other than human), or any combination of these sources of male ejaculate.
Said male ejaculate and/or male ejaculate fractions may be used as the only type of antigen source in the infertility vaccine or may be used in various amounts and concentrations, and in various combinations and concentrations with the various other antigen sources, mentioned herein.
This application claims the use of whole live ova as possible components in the creation of various infertility vaccines. Said ova may be human (autologous and/or allogenic), and/or animal (trans-specie, other than human), or may be used in any combination of these ova sources. Said whole live ova may be used as the only type of antigen source in the infertility vaccine or may be used in various amounts and concentrations, and in various combinations and concentrations with the various other antigen sources, mentioned herein.
This application claims the use of whole dead ova as possible components in the creation of various infertility vaccines. Said dead ova may be human (autologous and/or allogenic), and/or animal (trans-specie, other than human), or any combination of these ova sources. Said whole dead ova may be used as the only type of antigen source in the infertility vaccine or may be used in various amounts and concentrations, and in various combinations and concentrations with the various other antigen sources, mentioned herein.
This application claims the use of the fractions and/or biochemical components of ova, as possible components in the creation of various infertility vaccines. Said ova fractions may be human (autologous and/or allogenic), and/or animal (trans-specie, other than human), or any combination of these ova fraction sources. Said ova fractions may be used as the only type of antigen source in the infertility vaccine or may be used in various amounts and concentrations, and in various combinations and concentrations with the various other antigen sources, mentioned herein.
Methods of fractioning or separating or digesting or concentrationing said ova are not a part of this application. Examples of said fractions may be:
the partially digested plasma membrane of the ova, the protein fraction(s) of the ova, the complex carbohydrates fraction(s) of the ova, etc. But in no way does this application claim the use of only a particular isolated ovum-based protein or set of isolated ovum-based proteins. Said ova fractions or biochemical components may be derived from human ova (autologous and/or allogenic), and/or from animal (other than human) ova, or from any combination, thereof.
This application claims the use of all or portions/fractions of mucin as possible components in the creation of various infertility vaccines. Said mucin may be human (autologous and/or allogenic), and/or animal (trans-specie, other than human), or any combination of these mucin sources. Said mucin and/or mucin fractions may be used as the only type of antigen source in the infertility vaccine or may be used in various amounts and concentrations, and in various combinations and concentrations with the various other antigen sources, described herein.
This application claims the use of all or portions/fractions of the liquor folliculi (with and/or without ova) as possible components in the creation of various infertility vaccines. Said liquor folliculi may be human (autologous and/or allogenic), and/or animal (trans-specie, other than human), or any combination of these sources of liquor folliculi. Said liquor folliculi may be used as the only type of antigen source in the infertility vaccine or may be used in various amounts and concentrations, and in various combinations and concentrations with the various other antigen sources, described herein.
This application claims the use of whole or portions/fractions of live and/or dead, male and/or female, gamete germinal cells (GGCs) or immature gametes (GPCs), including polar bodies, as possible components in the creation of various infertility vaccines. Said gamete germinal cells or immature gametes may be human (autologous and/or allogenic), and/or animal (trans-specie, other than human), or any combination of these sources of GGCs and GPCs. Said gamete germinal cells or immature gametes, or fractions there of, may be used as the only type of antigen source in the infertility vaccine or may be used in various amounts and concentrations, and in various combinations and concentrations with the other antigen sources, described herein.
This application claims the use of differentiated stem cells and/or fractions/portions thereof as possible components in the creation of various infertility vaccines. Said differentiated stem cells may be derived from human (autologous and/or allogenic), and/or animal (trans-specie, other than human), or any combination of these stem cell sources. Said differentiated stem cells, or fractions there of, may be used as the only type of antigen source in the infertility vaccine or may be used in various amounts and concentrations, and in various combinations and concentrations with the various other antigen sources described, herein. Said differentiated stem cells may have been differentiated into any of the following:
sperm, ova, immature gametes (including polar bodies), and/or gamete germinal cells. Said differentiated stem cells may be used as the only antigen source in the infertility vaccine or may be used in various amounts and concentrations, and in various combinations and concentrations with the various other antigen sources, described herein.
This application claims the use of any and all of the aforementioned antigen sources {[0005 through [0034]}, in all of the possible combinations and concentrations, as possible components in the creation of various infertility vaccines, without claiming the use of an identified or isolated sperm antigen.

15 more elements

Polyantigenic-based (multiple antigens) modi or set of methods for developing infertility vaccines

Life of this patent

Polyantigenic-based (multiple antigens) modi or set of methods for developing infertility vaccines

Life of this patent

Abstract

Claims1